The existence of a slow-cycling subpopulation of MYBBP1A negative tumor cells in HNSCC patients could be of high clinical importance since most current therapeutic regimens target the rapidly proliferating tumor bulk. The gene discussed is MYBBP1A; the disease is neoplasm.